Platypus Technologies signed an agreement granting Cell Biolabs a license to use its cell exclusion zone technology. The deal allows Cell Biolabs to incorporate the technology into its CytoSelect™ cell-migration assays.
“There is a growing demand for cell motility assays that allow visual assessment of cell morphology,” says Renee Herber, program manager at Platypus. “This partnership should allow us to service a greater number of researchers for whom more data per assay well is critical.”
Cell Biolabs develops and commercializes assays and reagents to advance cell and molecular biology. Platypus’ Oris™ cell-based assay line is designed to aid life science researchers studying cell migration and cell invasion.
Last October, the company launched the latest product in the Oris line, the Oris™ Pro 384 Cell Migration Assay. It is reportedly designed for high-throughput screening of chemical libraries for cancer therapeutics. The assay was developed using a $396,000 Innovative Molecular Analysis Technologies grant from the NCI.